Great Novel Therapeutics Biotech & Medicals Corporation

Great Novel Therapeutics Biotech & Medicals Corporation is a biotechnology company dedicated to the research and development of innovative therapies for advanced and refractory cancers. Founded in 2013 and based in Taipei, Taiwan, the company focuses on developing novel oral anti-cancer drugs and cancer immunotherapies that target complex tumor biology. Its primary products include TM/Kepida, an oral targeted therapy mainly used for relapsed and refractory peripheral T-cell lymphoma and certain subtypes of advanced breast cancer, as well as its own pipeline of tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. Great Novel Therapeutics Biotech & Medicals also invests in the creation of drug combinations designed to enhance immunotherapy effectiveness by modifying the tumor environment, ultimately aiming to activate the patient’s immune system and achieve lasting clinical benefits. With a small but specialized workforce, the company’s efforts are positioned at the forefront of immuno-oncology, contributing new therapeutic options to the healthcare sector and addressing unmet needs in cancer treatment through scientific innovation.